| Identification | Back Directory | [Name]
Pyrido[4,3-d]pyrimidin-7(6H)-one, 8-(4-chlorophenyl)-6-(2-methyl-2H-indazol-5-yl)-2-[(2,2,2-trifluoroethyl)amino]- | [CAS]
2377491-54-6 | [Synonyms]
AGI-43192
Pyrido[4,3-d]pyrimidin-7(6H)-one, 8-(4-chlorophenyl)-6-(2-methyl-2H-indazol-5-yl)-2-[(2,2,2-trifluoroethyl)amino]- | [Molecular Formula]
C23H16ClF3N6O | [MOL File]
2377491-54-6.mol | [Molecular Weight]
484.86 |
| Chemical Properties | Back Directory | [Boiling point ]
601.1±65.0 °C(Predicted) | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 83.33 mg/mL (171.86 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
6.69±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Biological Activity]
AGI-43192 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-43192 is a potent, but limited brain-penetrant compound. AGI-43192 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease[1]. | [storage]
Store at -20°C | [References]
[1]. Li M, et al. Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads. J Med Chem. 2022;65(6):4600-4615. |
|
|